Advanced Filters
noise
Found 842 clinical trials
N Neha Rupeja, MS

Sirtuin-NAD Activator in Alzheimer's Disease

The primary objectives are to: To determine whether MIB-626, after its daily oral administration, penetrates the blood-brain barrier in humans by measuring the cerebrospinal fluid (CSF) concentrations of MIB-626 and its key metabolites, nicotinamide (NAM), NR, 2-PY, and MeNAM at baseline and on day 90 at steady state. To evaluate …

55 - 85 years of age All Phase 1/2
N Nilanjan Sarkar, PhD

Use of Socially Assistive Robots for Long Term Care Older Adults With Cognitive Impairment and Apathy

The objective of this study is to demonstrate the impact of a socially assistive robot system on reducing apathy among cognitively impaired older adults residing in long term care facilities. Earlier phases of this project demonstrated the feasibility and acceptability of the robotic system. First, investigators will improve the social …

65 years of age All Phase 1/2
C Christina Hugenschmidt, PhD

Effects of Dance and Music Appreciation on Brain Health and Fitness in People at Risk for Alzheimer's Disease

The purpose of this research study is to study the effects of dance movement and music on memory and cardiorespiratory fitness in older adults who are concerned about memory loss. The study aims to determine the optimal number of movement or music appreciation classes a week to support brain health …

65 years of age All Phase N/A
G Galen Ziaggi

Discovery and Validation of Genetic Variants Affecting Microglial Activation in Alzheimer's Disease

The primary objectives are to validate that a previously identified gene variant influences the proportion of activated microglia (PAM) and the amount of TSPO binding on PET imaging, to identify novel loci that influence PAM and TSPO PET, and to understand the functional consequences of gene variants that drive microglial …

50 years of age All Phase 2
P Pei-Ling Peng

A Study of Oral EX039 in Subjects With Mild Alzheimer's Disease

This is a phase 2, randomized, double-blind, placebo-controlled study of oral EX039 as add-on to Acetylcholine Esterase Inhibitors in subjects with mild Alzheimer's disease.

50 - 80 years of age All Phase 2
M Mathieu CECCALDI, Prof.

Evaluating the Effectiveness of a New Way of Organizing Primary Health Care to Improve the Management of Alzheimer's Disease

The objective of the present study is to evaluate the effectiveness of a general practitioner (MG) management strategy guided by a multidimensional evaluation on the multidimensional score of fragility of patients with mild to moderately severe dementia, compared to those currently implemented (without the provision of such an assessment). The …

65 years of age All Phase N/A
A Anna-Chloé BALAGEAS, PhD

Effects of Auditory Brain Stimulation by "Pink Noise" on Memory Capacities in Alzheimer's Disease: Proof of Concept Study

Alzheimer's disease (AD) is a neurodegenerative disorder affecting almost 6% of the world's population over the age of 65. This disease, in its most typical sporadic form, is characterized by an episodic memory impairment linked to a deficit in consolidation. Many studies indicate that sleep promotes this consolidation stage during …

50 years of age All Phase N/A
T Timber Bourassa, BS

Phase II Trial to Evaluate Safety and Efficacy of GM-CSF/Sargramostim in Alzheimer's Disease

A medicine that is FDA-approved for bone marrow stimulation (called sargramostim) will be tested for its safety and efficacy in individuals with mild-to-moderate Alzheimer's disease over a six month treatment period.

60 - 85 years of age All Phase 2
C Cristina Toedebusch, BS

DORA and LP in Alzheimer's Disease Biomarkers

The purpose of this study is to see if the sleep aid, lemborexant, can decrease the amount of amyloid-beta and tau in the fluid around the brain known as cerebrospinal fluid (CSF). Amyloid-beta and tau are proteins involved in the disease process leading to Alzheimer's disease.

65 years of age All Phase 2
M Ming-Che Liu, Director of Clinical Research Center, MD, PhD

Evaluation of the Safety, Tolerability, and Pharmacokinetics of J4 in Healthy Adults

A Phase I, Randomized, Double-blinded, Placebo-Controlled First-in-human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of J4 Dry Powder Capsule after Oral Administration of Single and Multiple Ascending Doses to Healthy Adults

18 - 64 years of age All Phase 1

Simplify language using AI